中国医学科学院药物研究所（以下简称“药物所”）成立于1958年8月，隶属于中国医学科学院北京协和医学院。
药物所始终以寻找和研究严重危害人民健康的重大疾病防治药物为主要方向，坚持以创新药物为重点，以天然产物为特色，应用基础研究和创新药物研发并重，推进产学研一体化进程，走出了一条有中国特色的新药创制之路。
药物所学科齐全，下设合成药物化学、天然药物化学、药理学、药物分析、生物合成、药物筛选、药物晶型、药物制剂、药物代谢、新药开发、安全评价等研究科室，具有很强的药物研发能力。近年来着重依靠平台建设，推动夯实自身实力，现建有天然药物活性物质与功能国家重点实验室，国家药物及代谢产物分析研究中心、国家新药开发工程技术研究中心、“重大新药创制”科技重大专项药物创新综合性平台、科技部创新人才培养示范基地，7个省部级重点实验室，5个院校级重点实验室/中心，同时拥有6家所属企业，构建了完整的产学研用生态循环体系。
药物所重视人才培养，截止至2022年7月8日，现有职工500余名，其中40%具有高级职称，先后拥有六名两院院士，以及130余名国家各级专家及人才称号获得者。
药物所是中国高级药学人才的培养基地。已培养硕、博毕业生2000余名。药学学科为国家教育部批准的一级重点学科，在2017年全国第四轮学科评估药学学科评估中名列榜首（A+），进入世界“一流学科”建设行列。2022年药学再次入选第二轮“双一流”建设学科名单。
建所六十年来，药物所已研制上市新药百余种, 获新药证书及药品注册批件132项，其中以人工麝香、高三尖杉酯碱、联苯双酯、双环醇、丁苯酞、金水宝、艾瑞昔布、丹参多酚酸、桑枝总生物碱等为代表的原创新药22项。以药物所作为第一完成单位共获得科技成果奖励200余项，其中国际及国家级奖项31项（国家科技进步一等奖3项）；持有的有效专利1300余项，获得授权的国内外专利580余项；共编写著作380余本。近年来，药物所加强基础研究，在cell等杂志上发表论文3800余篇。
药物所主办学术期刊有《药学学报》、Chinese Chemical Letters (CCL，中国化学快报)、Journal of Asian Natural Products Research (JANPR，亚洲天然产物研究杂志)及Acta Pharmaceutica Sinica B (APSB，药学学报英文刊)，三本英文期刊均为SCI收录期刊。其中APSB是我国唯一被SCI收录的药学综合性期刊，首个影响因子6.014，2021年影响因子为14.903。CCL 2021年影响因子为8.455。《药学学报》是青蒿素诺贝尔奖获奖关键论文的发表期刊。
在中国“十四五”的科技新征程中，药物所作为中国药物研发“国家队”中的一员，坚守初心、勇挑重担，贯彻新发展理念，践行“四个面向”，提升新药创制的综合实力，彰显服务社会的家国情怀。药物所人始终以“献身、创新、求实、协作”的精神为指引，牢记为人民谋求健康福祉的使命责任，努力为中国医药卫生事业的高质量发展贡献力量。
Institute of Materia Medica, Chinese Academy of Medical Sciences (HEREINAFTER referred to as "INSTITUTE of Materia Medica") was established in August 1958 under the Chinese Academy of Medical Sciences and Peking Union Medical College.
The institute has always been focused on finding and researching drugs for the prevention and treatment of serious diseases that seriously harm people's health. Adhering to the emphasis on innovative drugs and the feature of natural products, the institute attaches equal importance to the application of basic research and innovative drug research and development, promotes the integration process of industry, university and research, and walks out a road of new drug creation with Chinese characteristics.
The institute has a complete range of disciplines, including synthetic drug chemistry, natural drug chemistry, pharmacology, drug analysis, biosynthesis, drug screening, drug crystal, drug preparation, drug metabolism, new drug development, safety evaluation and other research departments, with strong drug research and development capabilities. Mainly rely on the platform construction in recent years, driven compaction strength, now has a state key laboratory for natural medicine active substance and function, the national drug and metabolic product analysis research center, national engineering research center for new drug development, "major drug discovery" science and technology major projects drug innovation comprehensive platform, Ministry of Science and Technology innovation demonstration base of personnel training, It has 7 provincial and ministerial key laboratories, 5 university-level key laboratories/centers, and 6 affiliated enterprises, thus establishing a complete ecological cycle system of industry-university-research-application.
The institute attaches great importance to talent cultivation. As of July 8, 2022, the institute has more than 500 employees, 40% of whom have senior professional titles, six academicians of Chinese Academy of Sciences and Chinese Academy of Sciences, and more than 130 national experts and talent winners at all levels.
The institute is a training base for senior pharmaceutical talents in China. It has cultivated more than 2000 masters and doctoral graduates. As A first-level key discipline approved by the Ministry of Education, pharmacy ranked first (A+) in the fourth round of national discipline Evaluation in 2017, and entered the ranks of the world's "first-class discipline" construction. In 2022, pharmacy was selected into the second round of "Double First-class" construction discipline list.
Over the past 60 years since its establishment, the institute has developed and marketed more than 100 new drugs and obtained 132 new drug certificates and drug registration approvals, including 22 original new drugs represented by artificial musky, hartaxoline, biphenyl diester, dicyclic alcohol, butylphthalide, gold shuibao, iericoxib, salvianolic acid, mulberry branch total alkaloid, etc. The institute of Pharmaceutical Sciences has been awarded more than 200 scientific and technological achievements, including 31 international and national awards (3 first prizes for National Scientific and technological Progress). The company has more than 1300 valid patents and more than 580 authorized domestic and foreign patents. He has written more than 380 books. In recent years, THE institute has intensified basic research and published more than 3,800 papers in cell and other journals.
Academic journals sponsored by the Institute include Chinese Chemical Letters (CCL), Journal of Asian Natural Products Research (JANPR, Asian Journal of Natural Products Research and Acta Pharmaceutica Sinica B (APSB), all of which are SCI indexed. APSB is the only comprehensive pharmaceutical journal included by SCI in China, with the first impact factor of 6.014 and 14.903 in 2021. CCL 2021 impact factor is 8.455. Chinese Journal of Pharmacy is the publishing journal of key papers of artemisinin Nobel Prize.
In the new journey of science and technology of China's "14th Five-year Plan", AS a member of the "national team" of China's drug research and development, IMD adheres to the original aspiration, bravely takes on the heavy burden, implements the new development concept, practices the "four Aspects", improves the comprehensive strength of new drug creation and demonstrates the national sentiment of serving the society. Guided by the spirit of "dedication, innovation, truth-seeking and collaboration", the institute always keeps in mind the mission and responsibility of seeking health and well-being for the people and strives to contribute to the high-quality development of China's medical and health cause.